News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Markets showed limited movement in the past hour amid lack of major headlines.
  • US equity futures were little changed as trading volumes remained near recent averages.
  • Treasuries were largely flat with the 10-year yield steady around the previous close.
  • Oil and gold prices were little changed amid no new geopolitical catalysts.
  • Major currencies traded rangebound against the dollar without fresh central bank comments.
  • No significant political or economic releases appeared in the past hour to shift market direction.

Latest Articles

FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara

FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara

Telix Pharmaceuticals has received FDA approval for Pixclara®, a novel radioactive diagnostic PET imaging drug indicated to differentiate recurrent or progressive glioma from treatment-related changes in both adult and pediatric patients. This first FDA-approved FET-PET imaging agent for glioma offers physicians enhanced diagnostic precision and tr…

Department of War Makes Landmark $450 Million Committed Investment in The Elmet Group to Secure America’s Tungsten Supply Chain

Department of War Makes Landmark $450 Million Committed Investment in The Elmet Group to Secure America’s Tungsten Supply Chain

The Elmet Group Co., a NASDAQ-listed U.S. provider of critical materials including tungsten, announced a $450 million committed investment from the U.S. Department of War to enhance domestic tungsten production and processing capabilities. The investment aims to reduce foreign dependence, expand manufacturing facilities in Maine, Michigan, and Ohio…

Goldman Sachs Sees November 2026 Rate Increase by Bank of England

Goldman Sachs Sees November 2026 Rate Increase by Bank of England

Goldman Sachs has revised its outlook for the Bank of England, now projecting a 25-basis-point rise in the bank rate in November 2026 after recent increases in energy costs, a larger-than-expected uptick in headline inflation and robust growth data. The bank still expects the BoE to hold at 3.75% in September and to pause after a potential November…

BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients

BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients

BioNTech, in collaboration with OncoC4, announced updated Phase 3 trial data showing that their investigational immunotherapy gotistobart significantly improves median overall survival to 18.5 months versus 10.0 months with standard chemotherapy in patients with previously treated squamous non-small cell lung cancer. The therapy's novel mechanism s…

Santander Brasil: A High-Return Bank Worth a Patient Long Trade

Santander Brasil: A High-Return Bank Worth a Patient Long Trade

Banco Santander (Brasil) trades at $6.02 with a $22.97B market cap, a 4.9% yield and improving technicals. The combination of above-average profitability, steady distributions and a supportive technical backdrop makes this a concrete long idea for investors willing to hold through Brazil macro noise for up to 180 trading days.

Markets Wobble as AI Safety Warnings and Hormuz Talks Delay Rattle Investors

Markets Wobble as AI Safety Warnings and Hormuz Talks Delay Rattle Investors

U.S. equity futures fell early Monday after high-level warnings about accelerating artificial intelligence development prompted investors to reassess the outlook for large-scale AI infrastructure spending. The selloff in Asia and Europe followed comments from Anthropic's CEO calling for a deliberate deceleration in frontier model development, suppo…

NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer

NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer

Nanobiotix announced complete safety and efficacy results from the Phase 1 trial evaluating JNJ-1900 (NBTXR3), a radiotherapy-activated nanoparticle, in 24 patients with inoperable, recurrent non-small cell lung cancer. The trial showed no dose-limiting toxicities and clinically meaningful local tumor control at lower re-irradiation doses, with a o…